About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT02207868

3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH

The aim of the study is to document the left and right ventricular function in patients with sclerodermia associated pulmonal arterial hypertension via 3D echocardiography. The results of this study s...

Lead sponsor: Regina Steringer-Mascherbauer•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Regina Steringer-Mascherbauer, MD

CONTACT

0043/732/7676 regina.mascherbauer@elisabethinen.or.at

Andrea Ploechl

CONTACT

0043/732/7676 andrea.ploechl@elisabethinen.or.at

Sponsors

Lead Sponsor

Regina Steringer-Mascherbauer

The 3D echocardiography could provide early and detailed information about the changes in the left and right ventricle. The prediction of sclerodermia associated pulmonary arterial hypertension (PAH) is rather adverse, so it makes sense to evaluate relevant changes of the left-ventricular longitudinal strain soon to adapt the PAH specific therapy accordingly.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•age \>17
•pulmonary arterial hypertension (PAH) associated with WHO group 1 who start a parenteral prostanoid-therapy
•written informed consent
•prostanoid naive
•no change of the PAH specific therapy within 3 weeks of the recruitment to the study

Exclusion Criteria

•pregnancy and lactation period
•Women of child bearing potential who do not use an effective and secure method for birth control
•severe chronic kidney insufficiency (glomerular filtration rate \<30), which will remain for more than 3 months
•liver-insufficiency Child C
•life expectancy shorter than the course of the study (for example because of malignant disease

Related studies

RECRUITINGPhase 3

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981 · Pulmonary Arterial Hypertension

RECRUITINGPhase 3

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029 · Pulmonary Arterial Hypertension

RECRUITINGPhase 3

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332 · Pulmonary Arterial Hypertension

RECRUITINGPhase 1/2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110 · Healthy Volunteers, Pulmonary Arterial Hypertension

Mobile Health Intervention to Improve Exercise in Pediatric PH

NCT06549452 · Pulmonary Arterial Hypertension

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 23, 2018Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment6

Start dateJun 2014

Last updatedMay 23, 2018

Condition

Pulmonary Arterial Hypertension

Locations shown

Krankenhaus der Elisabethinen Linz GmbH

Linz, Upper Austria

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 23, 2018Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions